Stablepharma Begins Final Human Trial for First Fridge-Free Vaccine
London, Wednesday, 7 October 2026.
Stablepharma has dosed the first patient in a pivotal 160-person Phase 2b trial for its fridge-free tetanus-diphtheria vaccine, which can withstand temperatures up to 40°C for six months.
Pivotal Trial Initiation and Technology
Stablepharma has successfully dosed the first participant in its pivotal Phase 2b clinical trial for SPVX02, a thermostable tetanus-diphtheria booster vaccine, marking a critical milestone in the company’s development timeline [1]. The dosing occurred on 6 October 2026 at a trial site in Manchester, UK, initiating a randomized, single-blind, non-inferiority study involving 160 healthy adult participants [1]. This study serves as the final clinical development step toward commercialization, designed to compare SPVX02 against the WHO-prequalified originator vaccine, Tetadif® [1]. The trial aims to generate robust clinical evidence on immunogenicity, safety, and tolerability to determine if this thermostable approach offers a practical alternative to conventional refrigerated vaccines [1].
The SPVX02 vaccine utilizes StablevaX™ technology, a lyophilized reformulation designed to remain stable at temperatures up to 40°C for at least six months [1]. Real-time stability studies indicate potency retention for 24 months at 30°C, addressing critical cold-chain supply constraints in global pharmaceutical logistics [1]. Previous Phase 1 human trial results published in eClinicalMedicine confirmed a strong safety profile and immune responses comparable to licensed Td vaccines, proving aluminium-adjuvanted vaccines can be reformulated for fridge-free use [1]. This technological capability seeks to transform vaccine distribution economics by eliminating cold-chain dependence for storage and distribution [1].
Strategic Partnership and Financial Context
AFT Pharmaceuticals, a key partner in the commercialization pathway, reported double-digit revenue growth across all divisions during the first half of FY27, reaffirming its annual revenue target of NZ$300 million [2][3]. The company maintains operating profit guidance between NZ$28 million and NZ$32 million, representing a guidance range spread of 4 million [2][3]. AFT has signed a letter of intent to distribute SPVX02 in the UK, Canada, Australia, and New Zealand, with options to expand to Singapore and Hong Kong [2][3]. This partnership aligns with AFT’s strategy to support FY27 revenue targets while mitigating geopolitical uncertainty through higher inventory positions [3].
The collaboration validates StablePharma’s technology following the publication of Phase I data, which provided independent validation of the science underpinning SPVX02 [1]. AFT’s management noted that demand remained supportive across operating regions, contributing to the confidence in hitting financial targets [3]. The distribution agreement positions both companies to strengthen healthcare worldwide by developing fridge-free versions of vaccines and other refrigerated medicines [1]. This strategic alignment underscores the financial and operational readiness required to move from clinical validation to market availability.
Commercialization Timeline and Market Potential
The companies anticipate launching the first fridge-free medicine product under the existing StablePharma agreement by 2029, marking a significant shift in pharmaceutical logistics [2][3]. The market for refrigerated medicines is estimated to be worth up to US$6 billion, representing a substantial addressable market for thermostable alternatives [2]. While SPVX02 represents the current focal point, the platform technology has broader potential to transform how temperature-sensitive medicines are stored and distributed worldwide [1]. Successful commercialization would eliminate cold-chain dependence, reducing costs and expanding access in regions with limited infrastructure [1].
Management indicated that the company is maintaining a higher inventory position to ensure supply continuity as part of its strategy to support FY27 revenue targets [3]. The Phase 2b trial results will help determine whether this approach to vaccine thermostabilization can offer a real, practical alternative product to conventional refrigerated vaccines [1]. With the first participant dosed on 6 October 2026, the event has occurred as scheduled, aligning with the article date of 7 October 2026 [1]. Future progress will depend on the outcomes of the 160-patient study and subsequent regulatory approvals leading to the 2029 launch target [2][3].